Studies pregnancy outcomes in people with lupus or antiphospholipid syndrome
Observes pregnant adults with lupus or antiphospholipid syndrome to see what predicts pregnancy problems.
Key facts
- Who runs it
- Hospital for Special Surgery, New York
- Where
- London, United KingdomSee the siteAlso in 2 other countries, 9 sites
- Trial code
- Registry title
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
- Status
- Recruiting
- People taking part
- 700 people, planned
- Started
- Sept 2003
- Expected to end
- Mar 2027
- Type of study
- Observational, 4 groups
- Record updated
- 28 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women who have lupus (SLE), antiphospholipid antibodies, both, or neither (healthy controls). It follows how the pregnancy goes.
- Age
- 18 to 45 years; under 18 can join with parental consent.
- Sex
- Women only (pregnant).
- Disease stage
- Live pregnancy of up to 12 weeks (no aPL antibodies) or up to 18 weeks (with aPL antibodies). Groups: aPL antibodies without SLE, aPL antibodies with SLE, SLE without aPL antibodies, and healthy controls.
- Biomarker or test result
- Positive aPL antibodies means a positive LAC, or aCL IgG or IgM at 40 units or more, or anti-β2GPI IgG or IgM at 40 units or more. Controls must have no positive aPL.
Main reasons for not taking part
- Diabetes (type I or type II) that started before the pregnancy
- Known or suspected inherited complement deficiency (CH50 = 0)
- Controls: a past fetal death, or more than 1 miscarriage before 10 weeks
- Controls: currently smoking or a medical problem needing long-term treatment
- Hematocrit of 26% or lower
This trial only enrols pregnant participants. The registry sentence this rests on: Patient pregnant with live intrauterine pregnancy, as defined by positive test for elevated β-HCG, but ≤ 12 weeks by gestation (for subjects without aPL antibodies) and ≤18 weeks (for subjects with aPL antibodies)
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patient pregnant with live intrauterine pregnancy, as defined by positive test for elevated β-HCG, but ≤ 12 weeks by gestation (for subjects without aPL antibodies) and ≤18 weeks (for subjects with aPL antibodies)
- Patient between the ages of 18-45 and able to give informed consent, or age < 18 years with parental consent
- Hematocrit > 26%
- For APL positive:; aCL: IgG >= 40 GPL units; IgM >= 40 MPL units; Positive LAC (RVVT, Kaolin, dilute TTI or PTT LA); Anti-β2GPI: IgG >= 40 GPL units; IgM >= 40 MPL units
- For control subjects:; At least one successful pregnancy; No history of fetal death (death of conceptus ≥ 10 weeks' gestation); No more than 1 miscarriage < 10 weeks' gestation; No history of positive aPL in local lab or positive aPL in core labs at screening; Not currently a smoker; No medical problems requiring chronic treatment
Who cannot take part
- Diabetes mellitus (Type I and Type II) antedating pregnancy
- Known or suspected hereditary complement deficiency (defined by CH50 = 0)
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Where in United Kingdom
Also in 2 other countries, 9 sites
- Guy's & St Thomas' NHS Foundation TrustLondon, United KingdomContact: Marta M. Guerra, MSNo longer taking part
About the trial
What the trial wants to find out
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE.
The 4 groups in the trial
- Group 1: aPL+/SLE-
Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM \>= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM \>= 40 units; no SLE
- Group 2: aPL+/SLE+
Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM \>= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM \>= 40 units AND SLE defined as four or more American College of Rheumatology criteria for SLE.
- Group 3: aPL-/SLE+
No antiphospholipid antibodies; SLE defined as four or more American College of Rheumatology criteria for SLE.
- Group 4: aPL-/SLE-
Healthy controls: no antiphospholipid antibodies; no SLE
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
- Plain-language title
- Studies pregnancy outcomes in people with lupus or antiphospholipid syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT00198068, who can take part
- Publications
- Low frequency of flares during pregnancy and post-partum in stable lupus patients.Arthritis research & therapy, 2020
- Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome.Lupus, 2018
- Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus.Arthritis care & research, 2018
- Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes.Arthritis & rheumatology (Hoboken, N.J.), 2016
- Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results.Lupus science & medicine, 2016
- Record updated
- 28 April 2026